Terns Pharmaceuticals Inc (TERN) has a current Price-to-Book (P/B) ratio of 12.36. Compared to its 3-year average P/B ratio of 2.17, the current P/B ratio is approximately 469.85% higher. Relative to its 5-year average P/B ratio of 1.74, the current P/B ratio is about 608.93% higher. Terns Pharmaceuticals Inc (TERN) has a Forward Free Cash Flow (FCF) yield of approximately -1.78%. Compared to its 3-year average FCF yield of -15.48%, the current FCF yield is approximately -88.50% lower. Relative to its 5-year average FCF yield of -21.83%, the current FCF yield is about -91.84% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for TERN competitors is 915.32, providing a benchmark for relative valuation. Terns Pharmaceuticals Inc Corp (TERN.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of TERN increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of TERN in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is TERN currently overvalued or undervalued?

What is Terns Pharmaceuticals Inc (TERN) fair value?

TERN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Terns Pharmaceuticals Inc (TERN) is between NaN to NaN according to relative valuation method.

How does TERN's valuation metrics compare to the industry average?

The average P/S ratio for TERN's competitors is 915.32, providing a benchmark for relative valuation. Terns Pharmaceuticals Inc Corp (TERN) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Terns Pharmaceuticals Inc (TERN) as of Mar 02 2026?

As of Mar 02 2026, Terns Pharmaceuticals Inc (TERN) has a P/B ratio of 12.36. This indicates that the market values TERN at 12.36 times its book value.

What is the current FCF Yield for Terns Pharmaceuticals Inc (TERN) as of Mar 02 2026?

As of Mar 02 2026, Terns Pharmaceuticals Inc (TERN) has a FCF Yield of -1.78%. This means that for every dollar of Terns Pharmaceuticals Inc's market capitalization, the company generates -1.78 cents in free cash flow.

What is the current Forward P/E ratio for Terns Pharmaceuticals Inc (TERN) as of Mar 02 2026?

As of Mar 02 2026, Terns Pharmaceuticals Inc (TERN) has a Forward P/E ratio of -31.32. This means the market is willing to pay $-31.32 for every dollar of Terns Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Terns Pharmaceuticals Inc (TERN) as of Mar 02 2026?

As of Mar 02 2026, Terns Pharmaceuticals Inc (TERN) has a Forward P/S ratio of 0.00. This means the market is valuing TERN at $0.00 for every dollar of expected revenue over the next 12 months.

TERN Valuation